Wang W, Zhang Z, Shang J, Jiang ZZ, Wang S, Liu Y et al. Activation of group I metabotropic glutamate receptors induces long-term depression in the hippocampal CA1 region of adult rats in vitro. Neurosci Res 62: 43-50
Previous studies have implicated that long-term depression (LTD) was developmentally regulated since LTD can be readily induced by low frequency stimulation (LFS) in acute hippocampal slices prepared from juvenile but not adult animals. Here, we have examined the LTD induced by LFS (1Hz, 900 pulses) paired with a certain pattern at the Schaffer collateral-CAl synapse in adult hippocampal slices. We found that, in the 90-day-old rat hippocampus, LTD could be induced reliably by LFS paired with stronger stimulus intensity than that used during baseline recording. However, this synaptic depression could be completely abolished by application of metabotropic glutamate receptor (mGluR) antagonist (S)-amethyl-4-carboxyphenylglycine (MCPG) which had no effect on that induced by the same protocol in the 16-day-old rat hippocampus. Furthermore, preincubation with group I mGluR antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and (S)-2-methyl-4-carboxyphenylglycine (LY367385), also completely prevented the LFS-induced LTD. In contrast, group II mGluR antagonist (2S)-a-ethylglutamic acid (EGLU), N-methyl-d-aspartate (NMDA) receptor antagonist APV and voltage-gated calcium channel antagonist nimodipine had no effect on the LFS-induced LTD. Taken together, these observations suggest that LFS paired with strong stimulus strength can efficiently induce group I mGluR-dependent LTD in the adult hippocampal CA1 region, proving insight into the functional significance of hippocampal mGluR-mediated LTD in learning and memory.
"Hippocampal LTD, mGluR5, and ECs Y Izumi and CF Zorumski Furthermore, it has been recently reported that LFS-LTD can be induced after DHPG-LTD (Wang et al, 2008). CHPG, a more specific mGluR5 agonist (Doherty et al, 1997), has been used less often for LTD studies, but has been found to induce or augment LTD in several studies (Palmer et al, 1997; Lanté et al, 2006; Neyman and Manahan-Vaughan, 2008). "
[Show abstract][Hide abstract] ABSTRACT: In the CA1 region of the rat hippocampus, metabotropic glutamate receptor-5 (mGluR5) and cannabinoid-1 receptors (CB1Rs) are believed to participate in long-term synaptic depression (LTD). How mGluRs and CB1Rs interact to promote LTD remains uncertain. In this study, we examined LTD induced by CB1R agonists, mGluR5 agonists, and low-frequency electrical stimulation (LFS) of the Schaffer collateral pathway. Synthetic CB1R agonists induced robust LTD that was mimicked by the endocannabinoid (EC), noladin ether (NLDE), but not by anandamide. 2-Arachidonylglycerol (2AG) produced only a small degree of LTD. The selective mGluR5 agonist, namely (RS)-2-chloro-5-hydroxyphenylglycine (CHPG), also induced robust LTD, and CHPG and NLDE occluded each other's effects. Similarly, CHPG and NLDE occluded LFS-induced LTD, and LTD resulting from all three treatments was blocked by a CB1R antagonist. CHPG-LTD and NLDE-LTD were insensitive to N-methyl-D-aspartate receptor (NMDAR) block, even though LFS-LTD requires NMDARs. LTD induced by LFS or CHPG, but not NLDE-LTD, was blocked by a selective mGluR5 antagonist. (RS)-3,5-dihydroxyphenylglycine (DHPG), a less selective group I mGluR agonist, also induced LTD, but its effects were not blocked by mGluR5 or CB1R antagonists. Furthermore, DHPG-LTD was additive with LFS-LTD and CHGP-LTD. These results suggest that NMDARs, mGluR5, and CB1Rs participate in a cascade that underlies LFS-LTD and that release of an EC and CB1R activation occur downstream of NMDARs and mGluR5. Furthermore, DHPG induces a form of LTD that differs mechanistically from LFS-induced depression.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 02/2012; 37(3):609-17. DOI:10.1038/npp.2011.243 · 7.05 Impact Factor
"LTD was effectively induced by prolonged low-frequency stimulation (LFS) of 1-5 Hz (Doyere et al., 1996; Dudek and Bear, 1992) in CA1 or by repeated low-frequency paired-pulse stimulation in CA1 and DG (Thiels et al., 1996). Metabotropic glutamate receptors (mGluRs), in addition to N-methyl-D-aspartate receptors (NMDARs), have been suggested to play a role in LTD in hippocampal CA1 (Kleppisch et al., 2001; Manahan-Vaughan, 1997; Neyman and Manahan- Vaughan, 2008; Wang et al., 2008). To our knowledge, there has been no study on LTD of the direct EC to CA3 pathway. "
[Show abstract][Hide abstract] ABSTRACT: Synaptic plasticity may depend not only on the afferent fibers but also on the recipient structure. The medial perforant path (MPP) from the entorhinalcortex projects to both the dentate gyrus (DG) and CA3, resulting in excitatory postsynaptic potentials (EPSPs) in both areas. In this study, we showed that long-term depression (LTD) following low-frequency stimulation of MPP was found only in CA3a, a CA3 subfield, but not in DG. Field potentials were recorded and current source density (CSD) analyzed in CA3a and DG following stimulation of MPP in urethane-anesthetized rats. MPP evoked a short-latency population spike (PS) and EPSP in CA3a, <2.5 ms delayed from the respective events in DG. A small electrolytic lesion of CA3a abolished the locally recorded PS in CA3a but did not affect the responses in the DG. Low-frequency stimulation of the MPP for 600 pulses at 5 Hz, but not at 1 Hz, resulted in LTD of up to 2 h in CA3a but not in DG. High-frequency stimulation (400 Hz bursts) of the MPP resulted in long-term potentiation (LTP) in both CA3a and DG. LTD at CA3a was blocked by a prior intracerebroventricular administration of an N-methyl-D-aspartate receptor (NMDAR) antagonist DL-2-amino-5-phosphonovaleric acid or a nonselective group I/II metabotropic glutamate receptor (mGluR) antagonist (RS)-α-methyl-4-carboxyphenylglycine. We conclude that an NMDAR and mGluR sensitive LTD is induced in CA3 but not in the DG following low-frequency MPP stimulation in vivo, and the bi-directional synaptic plasticity in CA3 may be responsible for its behavioral functions.
[Show abstract][Hide abstract] ABSTRACT: Glutamate is the main excitatory neurotransmitter in the central nervous system (CNS) and is a major player in complex brain functions. Glutamatergic transmission is primarily mediated by ionotropic glutamate receptors, which include NMDA, AMPA and kainate receptors. However, glutamate exerts modulatory actions through a family of metabotropic G-protein-coupled glutamate receptors (mGluRs). Dysfunctions of glutamatergic neurotransmission have been implicated in the etiology of several diseases. Therefore, pharmacological modulation of ionotropic glutamate receptors has been widely investigated as a potential therapeutic strategy for the treatment of several disorders associated with glutamatergic dysfunction. However, blockade of ionotropic glutamate receptors might be accompanied by severe side effects due to their vital role in many important physiological functions. A different strategy aimed at pharmacologically interfering with mGluR function has recently gained interest. Many subtype selective agonists and antagonists have been identified and widely used in preclinical studies as an attempt to elucidate the role of specific mGluRs subtypes in glutamatergic transmission. These studies have allowed linkage between specific subtypes and various physiological functions and more importantly to pathological states. This article reviews the currently available knowledge regarding the therapeutic potential of targeting mGluRs in the treatment of several CNS disorders, including schizophrenia, addiction, major depressive disorder and anxiety, Fragile X Syndrome, Parkinson's disease, Alzheimer's disease and pain.
DNA research: an international journal for rapid publication of reports on genes and genomes 03/2012; 10(1):12-48. DOI:10.2174/157015912799362805 · 3.05 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.